Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a, Randomised, Double-Blind, Placebo-Controlled, Two-Part Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetic Profiles of Inhaled Doses of NOC-100 in Adult Participants with Chronic Cough or Acute Cough, including Cough due to Postinfectious COVID-19

Next Previous
X
Search
Trial Profile

A Phase 2a, Randomised, Double-Blind, Placebo-Controlled, Two-Part Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetic Profiles of Inhaled Doses of NOC-100 in Adult Participants with Chronic Cough or Acute Cough, including Cough due to Postinfectious COVID-19

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 24 Nov 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Taplucanium (Primary)
  • Indications Cough
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Nocion Therapeutics

    • Most Recent Events

    • 22 Nov 2023 Status changed from recruiting to completed.
    • 12 Sep 2023 Planned number of patients changed from 120 to 130.
    • 31 Aug 2021 According to a Nocion Therapeutics media release, Jacky Smith is the global research lead for the study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top